【摘要】 目的观察重组人血管内皮抑制素(恩度)联合IFL方案(CPT-11+5-Fu/LV)治疗晚期结肠癌的近期疗效和毒副反应。方法试验组:恩度联合CPT-11+5-Fu/LV方案和对照组CPT-11+5-Fu/LV方案治疗晚期结肠癌共60例,共2～4周期,按照ERCIST标准和NCI-CTC标准分别评价二组的近期疗效和毒副反应。结果试验组有效率(RR)76.7%,疾病控制率(DCR)93.3%;对照组有效率(RR)46.6%,疾病控制率59.9%。二组对比差异有统计学意义(P<0.05)。近期毒副反应主要有胆碱能综合征,腹泻,骨髓抑制,胃肠道反应,口腔黏膜炎等,二组对比差异无统计学意义(P>0.05)。结论恩度联合IFL方案治疗晚期结肠癌,近期疗效提高,毒副反应不增加,安全性较好。更多还原

【Abstract】 Objective To observe the curative effect and the side effects of endostar(recombinant human endostatin,rh-endostain)combined IFL regimen [leucovorin(LV),5-fluorouracil(5-Fu)and Irinotecan(CPT-11)CPT-11+5-Fu/LV] in patients with advanced colorectal cancer.Methods A total of 60 patients with advanced colorectal cancer entered this trial.They were randomly and equally divided into endostar combined CPT-11+5-Fu/LV group and CPT-11+5-Fu/LV group.The cases were evaluated after at least 2-4 courses.The curative effect and the side effects were evaluated according to RECIST and NCI-CTC criteria.Results The response rate was 76.7% and the disease control rate was 93.3% in trial group.The response rate was 46.6% and the disease control rate was 59.9% in contral group.There were significantly difference between two groups(P<0.05).The main short-term toxicity effects were cholinergic syndrome,diarrhea,neutropenia,nausea,vomiting and mucositis,et al.There were no difference between the two groups(P>0.05).Conclusion Endostar combined CPT-11+5-Fu/LV in the treatment of advanced colorectal cancer patients were safe,effective and the toxicity is tolerable.更多还原